RTP Mobile Logo

Friday, May 18, 2018, Washington, DC, 6:00 AM – 7:30 AM

Oncology Grand Rounds: Nurse and Physician Investigators Discuss New Agents, Novel Therapies and Actual Cases from Practice — A 6-Part CNE Symposia Series Held During the 43rd Annual ONS Congress

PART 5 — Acute Leukemia

Event Details

Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room:
Independence A-E (Meeting Level 4)
Schedule (EST):
5:30 AM – 6:00 AM
Registration and Breakfast Buffet

6:00 AM – 7:30 AM
Educational Program
There is no registration fee for this event. Preregistration is highly recommended as seating and meal service are limited.

Bernadette M Cuellob, NP
Adult Care Nurse Practitioner
Memorial Sloan Kettering Cancer Center
New York, New York

Eytan M Stein, MD
Hematologist and Medical Oncologist
Assistant Attending Physician
Leukemia Service
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Wendy Stock, MD
Anjuli Seth Nayak Professor of Leukemia Research
Director, Leukemia Program
The University of Chicago Medicine
Chicago, Illinois

Lauren Ziskind, NP
The University of Chicago Medicine
Hematology Oncology
Chicago, Illinois

Additional faculty to be announced

Neil Love, MD
Research To Practice
Miami, Florida
Meeting space has been assigned to provide a symposium supported by AbbVie Inc, Amgen Inc and Celgene Corporation during the Oncology Nursing Society’s (ONS) 43rd Annual Congress, May 16-20, 2018 in Washington, DC. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.


Cases Presented Will Include Discussion of the Following Topics:

  • MODULE 1: Management of IDH Mutation-Positive Acute Myeloid Leukemia (AML)
  • MODULE 2: Current and Emerging Treatment Options for Patients with FLT3 Mutations
  • MODULE 3: Care of Elderly Patients with AML
  • MODULE 4: Therapeutic Strategies for Treatment-Related AML
  • MODULE 5: Selection and Sequencing of Therapy for Acute Lymphoblastic Leukemia

CE Information

Target Audience:
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of acute leukemia.

Learning Objectives:
Upon completion of this activity, participants should be able to:

  • Appreciate the clinical and prognostic significance of specific cytogenetic and molecular abnormalities, and use this information to counsel patients with acute myeloid leukemia (AML) regarding the rationale for current diagnostic testing algorithms.
  • Recognize the importance of age, performance status and other disease-related factors in the selection and sequencing of therapy for patients with various presentations of AML.
  • Assess available research evidence with FDA-approved and emerging agents with inhibitory effects on FLT3, and use this information to guide clinical care and protocol opportunities for appropriate patients with AML.
  • Develop an understanding of the mechanism of action, available data and FDA-endorsed role of enasidenib for patients with relapsed/refractory AML and an IDH2 mutation.
  • Recognize the recent FDA approval of CPX-351 for newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, and discern how this agent can be optimally integrated into nonresearch care algorithms for these patients.
  • Apply the results of emerging clinical research to optimize the clinical and supportive care of young adult and adult patients with newly diagnosed and recurrent acute lymphoblastic leukemia.
  • Appreciate the biologic rationale for and efficacy and toxicity data with the use of chimeric antigen receptor-directed T-cell therapy and, as appropriate, facilitate patient access to treatment or clinical trials with this novel therapeutic approach.
  • Educate patients about the side effects associated with existing and recently approved therapies, and provide preventive strategies to reduce or ameliorate these toxicities.
  • Assess ongoing research studies evaluating investigational agents for patients with acute forms of leukemia, and obtain consent from these individuals for study participation.
Accreditation Statement:
Research To Practice is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

Credit Designation Statements:
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

To obtain a certificate of completion and receive credit for this event, nurses must sign in at the registration desk upon arrival, attend the entire activity and return a completed Educational Assessment and Credit Form upon exiting the activity.

ONC/ILNA Certification:
This activity will be submitted to the ONCC for ILNA verification.

Unlabeled/Unapproved Uses Notice:
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center. Any off-label use as declared by the FDA will be identified.

Content Validation and Disclosures:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CNE activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

Research To Practice staff and external reviewers — The scientific staff, planners, managers and reviewers for Research To Practice have no relevant conflicts of interest to disclose.

This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Celgene Corporation and Jazz Pharmaceuticals Inc.


Marriott Marquis Washington, DC
901 Massachusetts Ave NW
Washington, DC 20001
Hotel Phone: (202) 824-9200

Meeting Room: 
Independence A-E (Meeting Level 4)

The Marriott Marquis Washington, DC is the headquarters hotel for the 2018 ONS Congress and is within a short walking distance (0.2 miles) of the Walter E Washington Convention Center.



This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of acute leukemia.

There is no registration fee for this event. However, preregistration is highly recommended as seating is limited.

Registration for clinicians in practice

I am a practicing nurse or other healthcare provider involved in the treatment of cancer.

Registration for clinicians in practice »
Registration for other/industry professionals*

For all other professionals, we are unable to confirm seating at this time. If you would like to stand by for participation in this event, please provide your contact information. Should seats become available for the program, we will notify you.

Standby Registration for Other/Industry Professionals »

* Individuals employed by for-profit organizations, including financial institutions, biotech or pharmaceutical companies
To ensure seating, please check in at our onsite registration desk at least one half hour prior to the start of the meeting. We cannot guarantee seating after the start of the program.

Meal service will be provided to those who attend the program, based on availability.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future CME/CNE programs.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.